Evidence map›Paper›PMID 40988120›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

Patient-reported Perceptions, Experiences, and Preferences Around Intravenous and Oral Antibiotics for the Treatment of Staphylococcus aureus Bacteremia: A Descriptive Qualitative Study.

Genevieve Walls, Loughlin McGrath, Michael Trent Herdman, Anita J Campbell, Matthew P Cheng, Michael Marks, Jaap Ten Oever, Euna Sahng, Dafna Yahav, Steven Y C Tong and 4 more

Registry-linked trialAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07384702 (Phase 2 Platform Randomized, Multicentre and Open Trial on the Efficacy and Safety of Clopidogrel as Adjuvant Drug in Staphylococcus Aureus Bacteraemia), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07384702 phase2not yet recruitingnot on this map

Phase 2 Platform Randomized, Multicentre and Open Trial on the Efficacy and Safety of Clopidogrel as Adjuvant Drug in Staphylococcus Aureus Bacteraemia (CLOPI-SNAP)

TypeinterventionalSponsorFundación Pública Andaluza para la gestión de la Investigación en SevillaRan2026 to 2030Enrolled230ConditionsBacteremia Due to Staphylococcus AureusArmsClopidogrel, No antiplatelet treatment
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Genevieve WallsDepartment of Infectious Diseases, Middlemore Hospital, Te Whatu Ora Counties Manukau, Auckland, New Zealand.ORCID 0009-0003-9052-0682
Loughlin McGrathDepartment of Infectious Diseases, Middlemore Hospital, Te Whatu Ora Counties Manukau, Auckland, New Zealand.
Michael Trent HerdmanDepartment of Infectious Diseases, Middlemore Hospital, Te Whatu Ora Counties Manukau, Auckland, New Zealand.ORCID 0000-0002-4662-9352
Anita J CampbellDepartment of Infectious Diseases, Perth Children's Hospital, Perth, Western Australia, Australia.ORCID 0000-0002-5898-1126
Matthew P ChengDivision of Infectious Diseases, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-4867-2063
Michael MarksClinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID 0000-0002-7585-4743
Jaap Ten OeverDepartment of Internal Medicine and Community for Infectious Diseases, Radbound University Medical Centre, Nijmegen, The Netherlands.
Euna SahngDepartment of Infectious Diseases, Tauranga Hospital, Te Whatu Ora Hauora a Toi Bay of Plenty, Tauranga, New Zealand.ORCID 0009-0004-5664-374X
Dafna YahavInfectious Diseases Unit, Sheba Medical Centre, Ramat-Gan, Israel.ORCID 0000-0003-3181-9791
Steven Y C TongVictorian Infectious Diseases Service, the Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0002-1368-8356
Anna L GoodmanMedical Research Council Clinical Trials Unit, University College London, London, United Kingdom.
Anecita Gigi LimUniversity of Auckland, School of Nursing, Auckland, New Zealand.
Max BloomfieldDepartment of Infectious Diseases, Wellington Hospital, Te Whatu Ora Capital and Coast, Wellington, New Zealand.ORCID 0000-0002-3920-7151
Staphylococcus aureus Network Adaptive Platform Early Oral Switch Domain Specific Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is growing evidence to support partial oral antibiotic treatment of severe infections such as Staphylococcus aureus bacteremia, but clinical practice is slow to adopt this paradigm. We know little about how patients with severe infection experience and perceive intravenous and oral antibiotics in terms of quality of life and clinical effectiveness. We performed a qualitative study to elicit patients' views on treatment with intravenous and oral antibiotics, aiming to provide insights that could inform collaborative treatment decision-making.

methodsWe conducted semi-structured interviews with participants in the Staphylococcus aureus Network Adaptive Platform trial pharmacological sub-study PR-O-SNAP by telephone, in person, or via video conferencing. Interviews were recorded, transcribed and coded, and used to analyze and identify themes. Interviews occurred in 2 phases between November 2024 and January 2025, with interim analysis to refine interview questions between each phase.

resultsWe interviewed 17 patients who had received sequential intravenous then oral antibiotics for treatment of Staphylococcus aureus bacteremia. Overall, most participants preferred oral antibiotics for their convenience, which enabled improved mobility and independence, despite a perception that oral regimens were more complex and likely to cause side effects, and that intravenous antibiotics were more effective.

conclusionsChoosing a route of antibiotic administration for treatment of severe infection is a nuanced decision which should incorporate not just a patient's clinical status but also their preferences and personal context. Patient convenience and functional goals should be considered in treatment discussions between clinicians and patients.

Indexed as

Anti-Bacterial AgentsBacteremiaPatient PreferenceStaphylococcal InfectionsAdministration, IntravenousAdministration, OralAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedQualitative ResearchQuality of LifeStaphylococcus aureusAnti-Bacterial Agentsintravenous antibioticsoral antibioticspatient preferenceStaphylococcus aureus bacteremia

Identifiers

PMID40988120
PMCPMC13131953

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.